ライフサイエンスコーパス: rash

1 f adverse effects (of these, 67% were due to rash).

2 ne-tazobactam was discontinued in 1 patient (rash).

3 sory ganglia 3 dpi, before the appearance of rash.

4 hylactic treatment of erlotinib-induced skin rash.

5 t pain, respiratory distress, and a purpuric rash.

6 of eye irritation, respiratory illness, and rash.

7 uired dose reduction for grade 3 fatigue and rash.

8 Only 2 patients had rash.

9 lmonary infection with grade 3 maculopapular rash.

10 ere fatigue, nausea, headache, insomnia, and rash.

11 ad acute hypersensitivity, and 20 (2%) had a rash.

12 erity of adverse events, such as anaemia and rash.

13 throughout the cutaneous system as a papular rash.

14 papulopustular, and/or erythematous diffuse rash.

15 G (0.100 mg/kg) developed a generalised skin rash.

16 triple therapy increased risk for anemia and rash.

17 conjunctivitis followed by a characteristic rash.

18 al report of a typical itchy and/or flexural rash.

19 one patient developed a grade 3 drug-related rash.

20 gthened the time to the most severe grade of rash.

21 (50%) required dose reduction, 7 because of rash.

22 ), infusion-related reaction (16 [20%]), and rash (13 [16%]).

23 re patients in the nafcillin group developed rash (13.9% vs 4.2%; P = .002), renal dysfunction (11.4%

24 e [25%], pruritus [17%], diarrhea [13%], and rash [13%]), and 10% (95% CI, 8% to 13%) experienced gra

25 itinib and 208 [33%] patients on sorafenib), rash (15 [2%] patients on sunitinib and 95 [15%] patient

26 taneous squamous cell carcinoma (389 [12%]), rash (155 [5%]), liver function abnormalities (165 [5%])

27 Common adverse events of all grades included rash (1592 [49%]), arthralgia (1259 [39%]), fatigue (109

28 [37%]), pruritus (23 [26%] vs 16 [19%]), and rash (16 [18%] vs 15 [18%]).

29 [61.2%]), followed by burn (307 [23.0%]) and rashes (163 [12.2%]).

30 % aspartate aminotransferase), maculopapular rash (17%), and neutropenia (17%).

31 symptoms for all reports were pyrexia (19%), rash (17%), pain (13%), and arthralgia (13%).

32 37 [39%] of 96 patients vs 50 [26%] of 189), rash (19 [20%] vs 18 [10%]), alopecia (18 [19%] vs eight

33 % of patients, most commonly: fatigue (29%), rash (19%), nausea (14%), diarrhea (12%), pruritus (12%)

34 P < .001), and less likely to present with a rash (2% vs 15%; P = .010).

35 gemcitabine and cisplatin group) and grade 3 rash (20 [4%] vs one [<1%]).

36 st common grade 3-4 adverse events were skin rash (21 [27%] of 77 patients vs 20 [22%] of 92 patients

37 usea (33/5), pyrexia (28/0), fatigue (25/3), rash (23/3), decreased appetite (20/15), upper respirato

38 more high-grade hyperglycemia (40% v 9%) and rash (24% v 2%).

39 utropenia (33%), thrombocytopenia (19%), and rash (25%).

40 rrhea (36/8), fatigue (36/3), nausea (25/3), rash (25/3), pyrexia (20/3), and chills (20/0).

41 s ten [2%] patients in the erlotinib group), rash (29 [7%] vs 12 [3%]), and stomatitis (15 [3%] vs tw

42 ned lots, 4.2% high-dose, 0.0% placebo), and rash (3.8% combined lots, 3.8% high-dose, 1.5% placebo).

43 7 patients) and keratoacanthomas (34 [10%]), rash (30 [9%]), and abnormal liver function tests (38 [1

44 atigue (33 [11%] of 292 patients), acneiform rash (31 [11%]), dyspnoea (29 [10%]), and decreased neut

45 vents occurring with E + T versus E + P were rash (33.1% v 37.3%, respectively), diarrhea (34.6% v 41

46 pruritus (43%), anemia (42%), nausea (37%), rash (35%), and headache (26%); serious AEs were reporte

47 , thrombocytopenia (42%), fatigue (40%), and rash (40%); drug-related grade >/=3 events included thro

48 rexed and cisplatin group had more grade 3-4 rash (45 [15%] of 304 vs one [<1%] of 312 patients in th

49 hyperglycaemia (88 [15%] vs one [<1%]), and rash (45 [8%] vs none).

50 ts on dacomitinib vs no controls), acneiform rash (48 [10%] vs one [<1%]), oral mucositis (16 [3%] vs

51 rile neutropenia (14%), mucositis (11%), and rash (5%).

52 fatigue (81 [13%] vs 74 [20%]), and acne or rash (52 [8%] vs one [<1%]).

53 de) were diarrhea (including colitis) (64%), rash (58%), pyrexia (42%), nausea (38%), chills (36%), c

54 mia (42 [16%] vs 14 [11%], respectively) and rash (72 [27%] vs 33 [25%]) were similar in the simeprev

55 diarrhoea (83 patients, 64%), non-acneiform rash (77 patients, 60%), liver enzyme abnormalities (64

56 Rash (84 reports), itching (46 reports), and vomiting (3

57 The most common adverse effects were skin rash (9.1%) and fatigue (8%).

58 was defined as any recurrent eye disease or rash 90 days or more after quiescence of disease was not

59 Clinical features were skin rash (92%), pancytopenia (78%), and diarrhea (65%).

60 r syndrome is characterized by an urticarial rash, a monoclonal gammopathy, and clinical, histologica

61 ause of the expected occurrence of acne-like rash--a class effect of EGFR antibodies--that would have

62 Other common features were erythrodermic rash, abdominal distension, edema, and hepatitis.

63 e emotion, and negative urgency referring to rash action in the context of negative emotion.

64 gression, with positive urgency referring to rash action in the context of positive emotion, and nega

65 Skin rash also correlated with drug levels and tended to decr

66 7 to 12 weeks after immunosuppression, and a rash also developed in the monkey that was not immunosup

67 wo obligate criteria: a recurrent urticarial rash and a monoclonal IgM gammopathy, and two of the fol

68 ssion, resulted in only a mild and transient rash and a short-lived elevation of the body temperature

69 hts successful management of telaprevir skin rash and anal discomfort by switching to boceprevir.

70 {95.2-96.5%}]), whereas higher incidence of rash and angioedema were reported for protocols with <6

71 t frequently leading to dose reductions were rash and arthralgia or arthritis.

72 mans by infected mosquitoes and causes acute rash and arthritis, occasionally complicated by neurolog

73 Fever, rash and bone marrow suppression are the most common man

74 AEs) overall, more grade 3 and 4 AEs (mainly rash and diarrhea), more serious AEs, and more AEs leadi

75 ents can lead to dose limiting toxicities of rash and diarrhea.

76 vels of clinical outcomes, ranging from mild rash and fever to severe neurological complications and

77 Our patient developed a diffuse rash and fever with systemic signs and symptoms of sepsi

78 mplications, 88.4% displayed mild disease of rash and fever.

79 s syndrome, grade 4 hypotension with grade 3 rash and fevers, grade 4 aspartate aminotransferase (AST

80 VZV-immune RMs displayed no varicella rash and had lower SVV viral loads and earlier and stron

81 ggested a relationship between exposure, and rash and hyperglycemia.

82 ome is characterized by recurrent urticarial rash and monoclonal gammopathy, associated with clinical

83 than in the EFV-TDF-FTC group (2% vs. 10%); rash and neuropsychiatric events (including abnormal dre

84 Rash and photosensitivity frequencies were higher in the

85 nophilia increases the hazard rate of having rash and renal injury.

86 two of three additional patients had grade 3 rashes and one had grade 3 AST elevation.

87 ubjects with serious clinical AEs (1 with DR rash); and 1 subjects with serious laboratory AEs (1 wit

88 ities, hemorrhagic manifestations, petechial rash, and a severely dysregulated immune response.

89 The rates of infection, rash, and abnormalities on liver-function testing were h

90 case of a Tongan man presenting with fever, rash, and altered mental status.

91 tially severe symptoms including depression, rash, and anxiety.

92 merged to cause profound epidemics of fever, rash, and arthralgia throughout sub-Saharan Africa, Sout

93 associated with delayed engraftment, fever, rash, and central nervous system dysfunction.

94 k of the well-known adverse events of fever, rash, and convulsions within the first 14 days.

95 rgency department visits for asthma and skin rash, and Culex quinquefasciatus species-specific vector

96 ents in either group were fatigue, pruritus, rash, and diarrhea.

97 verse events were fatigue, headache, nausea, rash, and diarrhea.

98 t common adverse events included stomatitis, rash, and diarrhea.

99 Pruritus, headache, nausea, rash, and dizziness were higher with TVR plus PEG-IFN-al

100 sferase, increased alanine aminotransferase, rash, and dyspnoea being the most common.

101 ined as an illness with fever, maculopapular rash, and either cough, coryza or conjunctivitis.

102 n kinase inhibitor (PKI) include arthralgia, rash, and fatigue, which are reported in up to one third

103 acterized by fever, polyarthralgia, myalgia, rash, and headache.

104 verse events were fatigue, headache, nausea, rash, and insomnia.

105 ays), fever, depression, anorexia, petechial rash, and lymphopenia.

106 Adverse events (eg, lethargy, diarrhoea, rash, and nausea) improved during the first 3 months of

107 ing an acute illness characterized by fever, rash, and polyarthralgia.

108 ea, headache, dizziness, insomnia, pruritus, rash, and vomiting.

109 s that include severe joint and muscle pain, rashes, and fever, as well as prolonged periods of disab

110 , presenting with a constellation of fevers, rashes, and mucosal symptoms in many cases, which sugges

111 ars spirochetes from the dermis and that the rash appearance is not indicative of the efficacy of the

112 Patients experienced fever, skin rash, arthralgia and conjunctivitis.

113 elf-limiting illness characterised by fever, rash, arthralgia, and conjunctivitis.

114 er the onset of signs and symptoms including rash, arthralgia, headache, pruritus, myalgia, and fever

115 nt with travel to Haiti who developed fever, rash, arthralgias, and conjunctivitis.

116 pruritic descending macular or maculopapular rash, arthralgias, conjunctival injection, and headache;

117 ssive systemic inflammation including fever, rashes, arthritis, and organ-specific inflammation and a

118 inical manifestations that include fever and rash, as well as multiple organ failure (liver, kidney,

119 quent toxicities were diarrhea, fatigue, and rash associated with lapatinib.

120 des scapularis tick and the erythema migrans rash associated with Lyme disease.

121 endamustine in two (7%) patients and diffuse rash at 1.2 mg/kg brentuximab vedotin plus 70 mg/m(2) of

122 , FLG status, or report of an itchy flexural rash at 2 months.

123 ectant mother who had a febrile illness with rash at the end of the first trimester of pregnancy whil

124 tion, characterized by an intensely pruritic rash at the site of contact with allergens like poison i

125 3 [95% CI, -13.76 to 5.70]; P = .42) or skin rash (beta = -1.00 [95% CI, -6.92 to 4.92]; P = .74).

126 Patients on arm B had more rash, but treatment arms did not differ regarding rates

127 major symptoms reported in both groups were rash by 26 mothers (65.0%), fever by 9 mothers (22.5%),

128 to distinguish smallpox from other pustular rashes by description alone.

129 treatment of the most common irAEs including rash, colitis, hepatitis, endocrinopathies, and pneumoni

130 ded experiences, may provide a mechanism for rash decision making in adolescents.

131 In 4 monkeys, a zoster rash developed 7 to 12 weeks after immunosuppression, an

132 day for 4 weeks), reactive treatment (after rash developed, per grade of rash), or no treatment unle

133 The incidence of all grades of rash did not differ statistically among the three arms,

134 lege of Rheumatology (ACR) criteria of malar rash, discoid rash, photosensitivity, and oral ulcers, a

135 Trial withdrawals and adverse events of rash, dizziness, and dental discoloration were more freq

136 e it is not usually associated with fever or rash, does not recur more rapidly on rechallenge, and pr

137 in genes related to the EGFR pathway, or on rash during erlotinib therapy.

138 In the rituximab group, nausea and skin rash during infusion were common; transient acute arthri

139 ); and were less likely to have a history of rash during pregnancy (20.7% vs 61.4%, ratio 0.34 [95% C

140 and probable cases there was no history of a rash during pregnancy.

141 ase (three [4%]), and fatigue, maculopapular rash, dyspnoea, decreased lymphocyte count, and decrease

142 (three [8%]), hypertension (six [16%]), skin rash (eight [22%]), and pancreatitis (six [16%] patients

143 %] of 110 patients), muscle pain (ten [9%]), rash (eight [7%]), cough, dyspnoea, or other pulmonary s

144 rade 3 toxicities included keratoacanthomas, rash, fatigue, and arthralgia.

145 on mucositis (43.2% v. 33.3%, respectively), rash, fatigue, anorexia, and hypokalemia, but not more l

146 ne alphavirus that causes major epidemics of rash, fever, and debilitating arthritis.

147 eria for Schnitzler syndrome with urticarial rash, fever, arthralgia, and bone pain; 47% reported wei

148 3 (12%) reported an adverse event, including rash, fever, serum sickness, and anaphylaxis.

149 events in phase 1b were fatigue (nine; 75%), rash (five; 42%), and chills, decreased appetite, diarrh

150 d elimination of infectious virus during the rash followed by slow elimination of viral RNA.

151 fluid (OF) as an alternative to sampling of rashes for varicella zoster virus (VZV) genotyping and f

152 hyperglycaemia (seven [8%] of 92 patients), rash (four [4%]), and dyspnoea (three [3%]).

153 ma and neutropenia (five [63%] of eight) and rash (four [50%] of eight) for patients with follicular

154 oup vs one [2%] of 63 in the placebo group), rash (four [6%] vs none), and asthenia (four [6%] vs one

155 swelling, vesicular lesions (blisters), and rashes from days 1 to 42.

156 sociated with selumetinib included acneiform rash, gastrointestinal effects, and asymptomatic creatin

157 disease, potential adverse drug effects (eg, rash, gastrointestinal intolerance, bone marrow suppress

158 verse events of these grades were urticarial rash (grade 3, equally common in both groups), neutropen

159 nts under observation (grade 4 maculopapular rash, grade 3 nausea, grade 3 infection, grade 3 thrombo

160 Two dose-limiting toxicities (grade 3 rash; grade 4 thrombocytopenia) occurred at 2.23 mg/m(2)

161 We enrolled pregnant women in whom a rash had developed within the previous 5 days and tested

162 hilia were significantly more likely to have rash (hazard ratio [HR], 4.16; 95% CI, 2.54-6.83; P < .0

163 other neurovascular manifestations, livedoid rash, hepatosplenomegaly, and systemic vasculopathy in t

164 Rash, history of tick bite, thrombocytopenia, and hypona

165 rolimus and exemestane (the most common were rash, hyperglycaemia, and stomatitis, which each affecte

166 g-related adverse events were diarrhea, skin rash, hyperglycemia, and night blindness.

167 d treatment of a previously unknown poxvirus rash illness in a renal transplant patient.

168 measles or rubella in patients with febrile rash illness, especially when associated with internatio

169 and diarrhea in 2 patients, and grade 3 skin rash in 1 patient.

170 ies only after identification of heart block/rash in a child.

171 occurred in three (6%) patients, and grade 3 rash in one (2%) patient.

172 nvasive infection that presents as a diffuse rash in preterm and term infants.

173 llenge (PC) among children presenting with a rash in the course of amoxicillin treatment are currentl

174 o developed a maculopapular and erythematous rash in the groin, genitalia, and buttocks.

175 congenital TORCH infections since there is a rash in the mother and there are commonly ocular abnorma

176 gs in patients with TORCH infections include rash in the mother during pregnancy and ocular findings

177 the necessary treatment of erlotinib-induced rash in the second- or third-line setting of metastatic

178 in seven (19%), anemia in four (10.8%), and rash in three (8.1%).

179 Rashes in the third trimester of pregnancy were associat

180 Grade 3 or 4 acne-like rash (in 209 of 785 patients [27%] vs four of 805 [<1%])

181 s were neutropenia (in 50% of the patients), rash (in 29%), thrombocytopenia (in 13%), an inflammator

182 were thrombocytopenia (in 37% of patients), rash (in 34%), dry skin (in 32%), and abdominal pain (in

183 Rash incidence and severity, time to maximal rash, time

184 We defined CCC as a diffuse rash involving the body, extremities, face or scalp, and

185 Although itchy rash is a nonspecific manifestation, it may be considere

186 n of the disease, a large (>/=5-cm diameter) rash, known as an erythema migrans.

187 S To assess the prevalence of reported itchy rash lasting longer than 3 days among the general popula

188 median age, 11 years) and reported fever and rash less frequently, compared to cases from other US re

189 neurons (enteric zoster), but an absence of rash makes diagnosis difficult.

190 m the dermis is the principle determinant of rash morphology.

191 The condition's characteristic high fever, rash, mucositis, conjunctivitis, lymphadenopathy, and ex

192 oped based on duration of fever, severity of rash, multisystem involvement, and duration of symptoms

193 characteristic symptoms, including cutaneous rash, myalgia, and arthralgia, with the latter sometimes

194 often accompanied by fever (n = 15 [58%]) or rash (n = 14 [54%]).

195 matopoietic treatment-related AEs, including rash (n = 2) and transaminitis (n = 1), were observed in

196 of 210 patients with eosinophilia, including rash (n = 32), renal injury (n = 31), and liver injury (

197 were experienced by 18 patients (75%); only rash (n = 5; 21%) and pyrexia (n = 4; 17%) and occurred

198 se events were anaemia (n=2), fatigue (n=1), rash (n=1), and hypothyroidism (n=1).

199 ay (grade 3 diarrhoea [n=1] and grade 3 skin rash [n=1]).

200 events: elevated liver transaminases, n = 1; rash, n = 1).

201 grade 3/4 adverse events included acne-like rash, neutropenia, and fatigue.

202 at occurred in two or more patients included rash, neutropenia, fatigue, neuropathy, arthralgia, myal

203 phalitis in a healthy young man with neither rash nor radicular pain.

204 Neither vaccine viremia, rash, nor a significant antibody boost were observed fol

205 sulindac-erlotinib group, with an acne-like rash observed in 87% of participants receiving treatment

206 major toxicities, including absence of skin rash observed with other EGFR-directed agents.

207 Rash occurred more frequently in the ixazomib group than

208 Rash occurred more frequently with allopurinol (10% vers

209 Severe rashes occurred in two patients, resulting in the early

210 438 patients were referred to the IPESQ for rash occurring during pregnancy or for suspected fetal c

211 racteristically present with a maculopapular rash, often accompanied by an inoculation eschar.

212 Atopic dermatitis, defined as an itchy rash on typical locations from birth to 6 years.

213 tients reached >80 000 mIU/mL 3-4 days after rash onset and that of the index was <500 mIU/mL 9 days

214 hospitalized measles patients with a date of rash onset during 6 June-10 September 2011.

215 cimens, and on respirators on days 5-8 after rash onset.

216 iologic link was hospitalized on day 5 after rash onset.

217 at of the index was <500 mIU/mL 9 days after rash onset.

218 d lasting from 4 days before to 4 days after rash onset.

219 inib vs two [1%] of 159 given gefitinib) and rash or acne (15 [9%] patients given afatinib vs five [3

220 rade 3 or 4 drug-related adverse events were rash or acne (31 [10%] of 320 patients in the afatinib g

221 4 adverse events in the afatinib group were rash or acne (35 [14.6%] of 239 patients), diarrhoea (13

222 atinib-related grade 3-4 adverse events were rash or acne (37 [16%] of 229 patients in LUX-Lung 3 and

223 h afatinib (16 [4%] vs none), and of grade 3 rash or acne with erlotinib (23 [6%] vs 41 [10%]).

224 arrhoea (36, 7%), hypertension (36, 7%), and rash or desquamation (29, 6%).

225 %), diarrhoea (68.6%), alopecia (67.1%), and rash or desquamation (50.2%).

226 4% vs. 2%), as were cutaneous events such as rash or eczema (in 37% vs. 19%, including serious events

227 Rash or erythema due to APM was reported in 7 (37%) pati

228 e most common adverse events were diarrhoea, rash or erythema, hepatic adverse events, and neutropeni

229 Additionally, ten (36%) of 28 patients had rash or eschar, eight (29%) had lymphadenopathy, eight (

230 neutrophil transudation during colitis, skin rash or peritonitis.

231 solated unconjugated hyperbilirubinemia, and rash or photosensitivity were more common in the active

232 None developed rash or viremia, but all showed evidence of infection.

233 ; 95% confidence interval (CI): 1.01, 1.66], rash (OR = 1.27; 95% CI: 1.02, 1.57), and earache (OR =

234 ory illness (OR = 1.37; 95% CI: 1.12, 1.67), rash (OR = 1.32; 95% CI: 1.05, 1.66), eye irritation (OR

235 reatment (after rash developed, per grade of rash), or no treatment unless severe (grade 3).

236 Cases of nausea, rash, or diarrhoea were significantly more common in the

237 rent transverse myelitis and a vesicobullous rash over her arms and feet that was pruritic and excori

238 NV, ZIKV patients were more likely to have a rash (P < .001) and less likely to be febrile (P < .05)

239 orphology of cutaneous lesions, treatment of rash, peripheral blood eosinophil count, tumor response,

240 tify immune factors present during the acute rash phase of measles and associations with outcome and

241 tology (ACR) criteria of malar rash, discoid rash, photosensitivity, and oral ulcers, and 3 (23%) met

242 Rash, photosensitivity, nausea, vomiting, and diarrhea w

243 sitivity syndrome, and 46 nevirapine-induced rash plus 3 with both DILI and SJS phenotype) and 155 ag

244 solation, developed disseminated zoster with rash present for 1 day before being transferred to the i

245 erapy was started empirically at the time of rash presentation and continued for a median (interquart

246 C) is a challenging diagnosis due to various rash presentations.

247 events attributed to treatment were fatigue, rash, pruritus, and diarrhea; most of the adverse events

248 skin and subcutaneous tissue disorders (eg, rash, pruritus, and urticaria) with insulin glargine.

249 most commonly reported adverse effects were rash, pruritus, fatigue, and insomnia.

250 ch-site) adverse events (including erythema, rash, pruritus, hyperpigmentation, pain, hypopigmentatio

251 hemotherapy (less hematologic toxicity; more rash, pruritus, neuropathy, and alopecia).

252 cluding fatigue, insomnia, irritability, and rash/pruritus.

253 apparent treatment failures in cases of skin rash, raising questions about the efficacy or suitabilit

254 ia and subsequent HSRs, including documented rash, renal injury, and liver injury.

255 Both patients' rashes resolved within 72 h of increasing immunosuppress

256 igh levels of proinflammatory cytokines, and rash) resolved within 2 hours of AP1903 infusion.

257 ues and their mothers do not report having a rash, screening criteria must be revised in order to det

258 umerous papules and pustules--similar to the rash seen in patients receiving EGFR inhibitor drugs.

259 imary factors controlling the speed that the rash spreads, whereas the rate that active macrophages a

260 %] of 154 vs ten [7%] of 152 with imatinib), rash (ten [6%] of 154 vs two [1%] of 152 with imatinib).

261 e age-standardized prevalence rates of itchy rash that lasted longer than 3 days.

262 odds ratio = 9.6; 95% CI, 1.5-64.0), while a rash that lasted longer than 7 days (adjusted odds ratio

263 VZV reactivation can occur in the absence of rash, the virological tests proving that VZV caused dise

264 adverse event in the AZD8931 group was skin rash (three [20%] of 15 patients with available data vs

265 sented with fever, four had diffuse or focal rash, three had symptoms suggestive of neurological incl

266 o this hospital because of fever, confusion, rash, thrombocytopenia, and renal failure, 10 days after

267 Rash incidence and severity, time to maximal rash, time to resolution, and overall survival (OS) were

268 ng from a single bone lesion or trivial skin rash to an explosive disseminated disease.

269 hs, respectively) than those who received no rash treatment (6 months).

270 [4%] vs two [2%] postoperatively), and skin rash (two [1%] vs 21 [15%] preoperatively; 0 vs eight [8

271 were ALT elevation (two [67%] of three) and rash (two [67%] of three) for patients with mantle cell

272 une response led to protection from disease (rash/viremia) but not from infection.

273 When these complications occur without rash, VZV-induced disease can be diagnosed by detection

274 Erlotinib-induced skin rash was associated with improved CFS (P = .01).

275 Rash was correlated with a greater ORR and improved prog

276 The occurrence or the grade of rash was not associated with a better survival in the Ge

277 Rash was not self-limiting.

278 oxicities were reported, a high incidence of rash was observed (all grades 82%, grade 3 36%).

279 ection between 8 and 9 days, and a petechial rash was observed with moribund ferrets.

280 Grade 3 rash was significantly higher in the no-treatment arm.

281 ere grades 1/2; the prevalence of anemia and rash was similar in both groups.

282 grade 3 to 4 treatment-related AEs; grade 3 rash was the only grade 3 to 4 event occurring in more t

283 ent in the phenytoin group (only one, severe rash, was attributable to phenytoin) compared with two (

284 The overall prevalences of itchy rash were 19.3% (95% CI, 18.6%-20.0%) during the month p

285 ce rates for either recurrent eye disease or rash were 8%, 17%, and 25%, respectively.

286 ix classes based on temporal trajectories of rash were consistently identified in 2 population-based

287 First week mortality and history of rash were provided by the State medical teams.

288 Diarrhea, pruritus, and rash were the most common treatment-related adverse even

289 arch or reporting infants' adverse events or rashes were more likely to attend research clinics and c

290 caused by VZV reactivation with and without rash will improve diagnosis and treatment.

291 Possible drug rash with eosinophilia and systemic symptoms (DRESS) syn

292 SJS), toxic epidermal necrolysis (TEN), drug rash with eosinophilia and systemic symptoms (DRESS), an

293 ), toxic epidermal necrolysis (TEN), or drug rash with eosinophilia and systemic symptoms (DRESS), ar

294 omegalovirus) were suspected to trigger drug rash with eosinophilia and systemic symptoms or GVHD.

295 died from chronic GVHD or unrecognized drug rash with eosinophilia and systemic symptoms, the others

296 fatal and was subsequently diagnosed as drug rash with eosinophilia and systemic symptoms.

297 One such diagnosis is drug rash with eosinophilia and systemic symptoms.

298 ansplantation, gene therapy-treated mice had rashes with cellular tissue infiltrates, activated perip

299 onths of vaccination, he developed recurrent rashes with fever, malaise, weakness, hepatitis, weight

300 Although fever subsided within 3 days, the rash worsened and extended over the whole body, with som